Population analyses of sustained-release verapamil in patients: Effects of sex, race, and smoking

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 1, 2003, Pages 31-40

  Kang, Dongwoo ^a,b   Verotta, Davide ^a,b   Krecic Shepard, Mary Ellen ^a,b   Modi, Nishit B ^a,b   Gupta, Suneel K ^a,b   Schwartz, Janice B ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ALZA CORPORATION   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALAN SR; COVERA SR; VERAPAMIL;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY WEIGHT; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG CLEARANCE; DRUG FORMULATION; FEMALE; HEART SUPRAVENTRICULAR ARRHYTHMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RACE DIFFERENCE; RACEMIC MIXTURE; SEX DIFFERENCE; STEADY STATE; SUSTAINED RELEASE PREPARATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; CONTINENTAL POPULATION GROUPS; CORONARY DISEASE; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; HYPERTENSION; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; RACEMASES AND EPIMERASES; SEX FACTORS; SMOKING; TACHYCARDIA, SUPRAVENTRICULAR; VASODILATOR AGENTS; VERAPAMIL;

EID: 0037261288     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2003.21     Document Type: Article

References (54)

1. Busse D, Cosme J, Beaune P, Kroemer H, Eichelbaum M. Cytochromes of the P4502C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1995; 353:116-21.
2. Kroemer H, Gautier J, Beaune P, Henderson C, Wolf C, Eichelbaum M. Identification of P450 enzymes involved in metabolism of verapamil in humans. Arch Pharmacol 1993;348:332-7.
3. Stein W. Kinetics of the multidrug transporter (P-glycoprotein) and its reversal. Physiol Rev 1997;77:545-90.
4. Sandstrom R, Karlsson S, Knutson L, Lennernas H. Jejunal absorption and metabolism of R/S verapamil in humans. Pharm Res 1998;15:856-62.
5. Schwartz JB. Aging alters verapamil elimination and dynamics: single dose and steady-state responses. J Pharmacol Exp Ther 1990;255:364-73.
6. Schwartz JB, Troconiz I, Verotta D, Liu S, Capili H. Aging effects on stereoselective pharmacokinetics and pharmacodynamics of verapamil. J Pharmacol Exp Ther 1993;265:690-8.
7. Schwartz JB, Capili H, Daugherty J. Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1994;55:509-17.
8. Schwartz JB, Capili H, Wainer I. Verapamil stereoisomers during racemic verapamil administration: effects of aging and comparisons to administration of individual stereoisomers. Clin Pharmacol Ther 1994;56:368-76.
9. Krecic-Shepard M, Barnas C, Slimko J, Gorski J, Wainer I, Schwartz JB. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil. Clin Pharmacol Ther 1999;66:40-50.
10. Krecic-Shepard M, Barnas C, Slimko J, Jones M, Schwartz JB. Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans. J Clin Pharmacol 2000;40:219-30.
11. Krecic-Shepard ME, Barnas CR, Slimko J, Schwartz JB. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil. Clin Pharmacol Ther 2000;68:286-92.
12. Harris R, Benet L, Schwartz JB. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995;50: 222-39.
13. Dethy J, De Broux S, Lesne M, Longstreth J, Gilbert P. Stereoselective determination of verapamil and norverapamil by capillary electrophoresis. J Chromatogr B Biomed Appl 1994;654:121-7.
14. Beal SL, Sheiner LB, editors. NONMEM users' guide. San Francisco: NONMEM Project Group, University of California at San Francisco; 1991.
15. Akaike A. A new look at the statistical model identification problem. IEEE Trans Autom Contr 1974;19:716-23.
16. Harrison G. Height-weight tables. Ann Intern Med 1985; 103:489-94.
17. Fletcher C, Acosta E, Strykowski J. Gender differences in human pharmacokinetics and pharmacodynamics. J Adolesc Health 1994;15:619-29.
18. Hooper WD, Qing MS. The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans. Clin Pharmacol Ther 1990; 48:633-40.
19. Ho P, Triggs E, Bourne D, Heazlewood V. The effects of age and sex on the disposition of acetylsalicyclic acid and its metabolites. Br J Clin Pharmacol 1985;19:675-84.
20. Kristjansson F. Disposition of alprazolam in human volunteers: differences between genders. Acta Pharm Nord 1991;3:249-50.
21. Pritchard J. Bryson J, Kernodle A, Benedetti T, Powell J. Age and gender effects on ondansetron pharmacokinetics: Evaluation of healthy aged volunteers. Clin Pharmacol Ther 1992;51:51-5.
22. Nafziger A, Bertino J. Sex-related differences in theophylline pharmacokinetics. Eur J Clin Pharmacol 1989;37: 97-100.
23. Hunt C, Westerkam W, Stave G. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 1992;44:275-83.
24. Milano G, Cassuto-Viguier E, Thyss A. Santini J, Frenay M, Renee N, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol 1992;10:1171-5.
25. Prather R, Tu T, Rolf C, Gorsline J. Nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) in women and obese men compared with normal-sized men. J Clin Pharmacol 1993;33:644-9.
26. Lew K, Ludwig E, Milad M, Donovan K, Middleton E, Ferry J, et al. Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993;54:402-14.
27. Hulst L, Fleishaker J, Peters G, Harry J, Wright D, Ward P. Pharmacokinetics and drug disposition: effect of age and gender on tirilazad pharmacokinetics in humans. Clin Pharmacol Ther 1994;55:378-84.
28. Meffin P, Brooks P, Sallustio B. Alterations in prednisolone disposition as a result of time of administration, gender and dose. Br J Clin Pharmacol 1984;17:395-404.
29. Wilson K. Sex-related differences in drug disposition in man. Clin Pharmacokinet 1984;9:189-202.
30. Sasaki M, Tateishi T, Ebihara A. The effects of age and gender on the stereoselective pharmacokinetics of verapamil. Clin Pharmacol Ther 1993;54:278-85.
31. Thummel KE, O'Shea D, Paine MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
32. Greenblatt D, Abernethy D, Locniskar A, Harmatz J, Limjuco R, Shader R. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 1984;61:27-35.
33. Gorski J, Jones D, Haehner-Daniels B, Hamman M, O'Mara E, Hall S. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998;64:133-43.
34. Nishiyama T, Matsukawa T, Hanaoka K. The effects of age and gender on the optimal premedication dose of intramuscular midazolam. Anesth Analg 1998;86: 1103-8.
35. Austin K, Mather L, Philpot C, McDonald P. Intersubject and dose-related variability after intravenous administration of erythromycin. Br J Clin Pharmacol 1980;10: 273-9.
36. Gupta S, Atkinson L, Tu T, Longstreth J. Age and gender related changes in stereoselective pharmacokinetics and pharmacodynamics of verapamil and norverapamil. Br J Clin Pharmacol 1995;40:325-31.
37. Lukkari E, Hakonen T, Neuvonen P. The pharmacokinetics of oxybutynin is unaffected by gender and contraceptive steroids. Eur J Clin Pharmacol 1998;53:351-4.
38. Greenblatt D, Divoll M, Abernethy D, Ochs H, Harmatz J, Shader R. Age and gender effects on chlordiazepoxide kinetics: relation to antipyrine disposition. Pharmacology 1989;38:327-34.
39. Greenblatt D, Friedman H, Burstein E, Scavone J, Blyden G, Ochs H, et al. Trazodone kinetics: effect of age, gender, and obesity. Clin Pharmacol Ther 1987;42:193-200.
40. Marathe P, Greene D, Lee J, Barbhaiya R. Assessment of effect of food, gender, and intra-subject variability in the pharmacokinetics of avitriptan. Biopharm Drug Dispos 1998;19:153-7.
41. Barbhaiya R, Knupp C, Pittman K. Effects of age and gender on pharmacokinetics of cefepime. Antimicrob Agents Chemother 1992;36:1181-5.
42. Keung A, Eller M, Weir S. Single-dose pharmacokinetics of rifapentine in women. J Pharmacokinet Biopharm 1998;26:75-85.
43. Minto C, Schnider T, Egan T, Youngs E, Lemmens H, Gambus P, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil; I: model development. Anesthesiology 1997;86:10-23.
44. Gorski JC, Lin Z, Bruce MA, Craven R, Haehner-Daniels BD, Hall SD. The interaction between CYP3A substrates in the elderly [abstract]. Clin Pharmacol Ther 1999;65: 136.
45. Krecic-Shepard M, Park K, Slimko J, Schwartz JB. Gender and race influence clearance of nifedipine, a high affinity cytochrome P450 substrate [abstract]. J Investig Med 1998;46:289A.
46. Thummel K, Shen D, Podoll T, Kunze K, Trager W, Bacchi C, et al. Use of midazolam as a human cytochrome P450 3A probe; II: characterization of inter- and intra-individual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271:557-66.
47. Kim R, Leake B, Choo E, Dresser G, Kubba S, Schwarz U, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-99.
48. Krecic-Shepard M, Park K, Barnas C, Slimko J, Kerwin D, Schwartz JB. Race and sex influence clearance of nifedipine: results of a population study. Clin Pharmacol Ther 2000;68:130-42.
49. Rochon J. Application of GEE procedures for sample size calculations in repeated measures experiments. Stat Med 1998;17:1643-58.
50. Walle T, Byington R, Furberg C, McIntypre K, Vokonos P. Biologic determinants of propranolol disposition: results from 1308 patients in the beta-blocker heart attack trial. Clin Pharmacol Ther 1985;38:509-18.
51. Suwunmi A, Rashid T, Akinyinka O, Renwick A. Ethnic differences in nifedipine kinetics: comparisons between Nigerians, Caucasians, and South Asians. Br J Clin Pharmacol 1995;40:489-93.
52. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, Wilkinson GR. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 2000;68:82-91.
53. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001;27:383-91.
54. Mancinelli L, Frassetto L, Floren L, Dressier D, Carrier S, Bekersky I, et al. The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 2001;69:24-31.